Skip to main content Accessibility help
×
Home

Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data

  • Cindy Zadikoff (a1) (a2), Minh Duong-Hua (a3), Kathy Sykora (a3), Connie Marras (a1), Anthony Lang (a1) and Paula Rochon (a3) (a4)...

Abstract

Introduction:

Pergolide is an ergot derived dopamine agonist that is widely used for the treatment of Parkinson’s disease. Studies have found an association between pergolide and valvular heart abnormalities although there is still much to be learned about the clinical significance of the valvular changes, who is at risk, and whether there is duration of exposure effect.

Objective:

To assess the long term risk of hospital admissions for valvular heart disease (VHD) or congestive heart failure (CHF, a clinically overt outcome of VHD) in new users of pergolide compared to new users of levodopa. The secondary objective was to assess whether there are any characteristics that can predict who is at higher risk of developing this outcome.

Design:

Retrospective, population-based cohort study.

Setting:

Ontario, Canada.

Subjects:

Ontario residents aged 66 and older, newly started on treatment with either pergolide or levodopa.

Outcomes:

Admission to hospital with the most responsible diagnosis of congestive heart failure or valvular heart disease.

Results:

The risk for admission for valvular heart disease or congestive heart failure were higher in those with 1-4 years exposure to pergolide compared with no exposure to pergolide (VHD: hazard ratio 2.4, p = 0.04; CHF: hazard ratio 1.6, p =0.02). No such pattern was found with exposure to levodopa.

Conclusion:

Our study demonstrates that treatment with pergolide is associated with a higher risk of hospital admission for valvular heart disease or congestive heart failure and that this risk is greater in those with 1-4 years exposure than in those with less exposure. We did not find an increased risk beyond four years.

<span class='bold'>RÉSUMÉ:</span> <span class='bold'> <span class='italic'>Contexte:</span> </span>

Le pergolide est un agoniste de la dopamine qui est dérivé de l’ergot. Il est couramment utilisé dans le traitement de la maladie de Parkinson. Des études ont mis en évidence une association entre le pergolide et des anomalies valvulaires cardiaques. Cependant on ne connaît pas la signification clinique des changements valvulaires, quels patients sont à risque et si la durée d’exposition a un effet

<span class='bold'> <span class='italic'>Objectif:</span> </span>

Le but de cette étude était d’évaluer le risque à long terme d’hospitalisation pour maladie cardiaque valvulaire (MCV) ou insuffisance cardiaque congestive (ICC, une conséquence clinique de la MCV) chez des patients qui prennent du pergolide depuis peu et chez des patients qui prennent de la lévodopa depuis peu. L’objectif secondaire était d’évaluer s’il existe des caractéristiques qui pourraient prédire qui est à plus haut risque de MCV.

<span class='bold'> <span class='italic'>Plan d’étude</span> </span>

Il s’agit d’une étude rétrospective de cohorte tirée de la population.

<span class='bold'> <span class='italic'>Cadre:</span> </span>

Cette étude a été effectuée en Ontario, au Canada.

<span class='bold'> <span class='italic'>Sujets:</span> </span>

Nous avons examiné les données de résidents de l’Ontario, ages de 66 ans et plus, qui prenaient du pergolide ou de la lévodopa depuis peu

<span class='bold'> <span class='italic'>Critères d’évaluation:</span> </span>

Un diagnostic d#x2019;ICC ou de MCV comme motif principal d#x2019;hospitalisation. Résultats : Le risque d#x2019;admission pour MCV ou ICC était plus élevé chez ceux qui avaient été exposés pendant 1 à 4 ans au pergolide par rapport à ceux qui n#x2019;y avaient pas été exposés (MCV ; rapport de risques 2,4 p = 0,04; ICC : rapport de risques 1,6 p = 0,02), ce qui n#x2019;était pas le cas pour la lévodopa.

<span class='bold'> <span class='italic'>Conclusion:</span> </span>

Cette étude démontre que le traitement par le pergolide est associé à un risque plus élevé d#x2019;hospitalisation pour MCV ou ICC et que ce risque est plus élevé chez ceux qui y ont été exposés pendant 1 à 4 ans que chez ceux dont la durée d#x2019;exposition est moindre. Le risque n#x2019;augmentait pas davantage si la durée d#x2019;exposition était de plus de 4 ans.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data
      Available formats
      ×

Copyright

References

Hide All
1. Hendrikx, M, Van Dorpe, J, Flameng, W, Daenen, W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis. 1996; 5:2357.
2. Redfield, MM, Nicholson, WJ, Edwards, WD, Tajik, AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med. 1992; 117:502.
3. Flaherty, KR, Bates, JR. Mitral regurgitation caused by chronic ergotamine use. Am Heart J. 1996; 131:6036.
4. Pritchett, AM, Morrison, JF, Edwards, WD, Schaff, HV, Connolly, HM, Espinosa, RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002; 77:12806.
5. Pergolide mesilate: strengthened warning. WHO Drug Information v17il, 37.2003.
6. Health Canada Warning. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2004/shire_permax_hpc-cps_e.html
7. Pergolide pulled from market. 2007. http://www.fda.gov/cder/drug/advisory/pergolide.htm
8. Connolly, HM, Crary, JL, McGoon, MD, Hensrud, DD, Edwards, BS, Edwards, WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337:5818.
9. Robiolio, PA, Rigolin, VH, Wilson, JS, Harrison, JK, Sanders, LL, Bashore, TM, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995; 92:7905.
10. Millan, MJ, Maiofiss, L, Cussac, D, Audinot, V, Boutin, JA, Newman-Tancredi, A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002; 303:791804.
11. Van Camp, G, Flamez, A, Cosyns, B, Goldstein, J, Perdaens, C, Schoors, D. Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology. 2003; 61:85961.
12. Zanettini, R, Antonini, A, Gatto, G, Gentile, R, Tesei, S, Pezzoli, G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007; 356:3946.
13. Baseman, DG, O’Suilleabhain, PE, Reimold, SC, Laskar, SR, Baseman, JG, Dewey, RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004; 63:3014.
14. Peralta, C, Wolf, E, Alber, H, Seppi, K, Muller, S, Bosch, S, et al. Valvular heart disease in Parkinson’s disease vs. controls: An echocardiographic study. Mov Disord. 2006; 21:110913.
15. Waller, EA, Kaplan, J, Heckman, MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2005; 80:101620.
16. Zadikoff, C, Rochon, P, Lang, A. Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci. 2006; 33:2733.
17. Van Camp, G, Flamez, A, Cosyns, B, Weytjens, C, Muyldermans, L, Van Zandijcke, M, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004; 363:117983.
18. Kim, JY, Chung, EJ, Park, SW, Lee, WY. Valvular heart disease in Parkinson’s disease treated with ergot derivative dopamine agonists. Mov Disord. 2006; 21:12614.
19. Lee, DS, Donovan, L, Austin, PC, Rouleau, JL, Liu, PP, Naimark, D, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005; 43:1828.
20. Levy, AR, O’Brien, BJ, Sellors, C, Grootendorst, P, Willison, D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003; 10:6771.
21. Barker, WH, Mullooly, JP, Getchell, W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation. 2006; 113:799805.
22. Schneeweiss, S, Seeger, JD, Maclure, M, Wang, PS, Avorn, J, Glynn, RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001; 154:85464.
23. Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:37383.
24. Schade, R, Andersohn, F, Suissa, S, Haverkamp, W, Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007; 356:2938.
25. Singh, JP, Evans, JC, Levy, D, Larson, MG, Freed, LA, Fuller, DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999; 83:897902.

Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data

  • Cindy Zadikoff (a1) (a2), Minh Duong-Hua (a3), Kathy Sykora (a3), Connie Marras (a1), Anthony Lang (a1) and Paula Rochon (a3) (a4)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed